Consistent with these gene-level signals, RYGB HFD mice displayed elevated fecal lipid content, lower plasma adiponectin, and increased liver glycogen relative to RYGB Chow, along with other tissue specific deficits such as greater bone mineral density loss and vitamin D deficiency, thereby showing that a HFD can still significantly constrain RYGB’s therapeutic scope [5]. The gene discussed is ADIPOQ; the disease is vitamin D deficiency.